Literature DB >> 19426245

Performing repeated noninvasive bedside measures of volume response to intravenous furosemide in acute pulmonary edema: a feasibility assessment.

Marie J Ng Kam Chuen1, Gregory Y H Lip, Robert J Macfadyen.   

Abstract

Optimizing responses to intravenous furosemide (ivF) in acute pulmonary edema is limited by current insensitive noninvasive means of volume assessment. We conducted a pilot study to assess the feasibility of performing repeated measures of echocardiographic and bioimpedance analysis (BIA) parameters and test their response as noninvasive markers of volume response to ivF. We also aimed to identify the most potentially sensitive markers of this response. Patients receiving ivF for a clinical diagnosis of acute cardiogenic pulmonary edema were studied. Echocardiographic and BIA parameters were measured at 0, 0.5, 1, 2, and 3 h after ivF. Intraobserver variability for each parameter was determined. Thirty-one patients were enrolled who were receiving 40-100 mg of ivF. Transmitral (MV) early peak velocity following Valsalva maneuver and transtricuspid (TV) early peak velocity reduced significantly (P= 0.012 and 0.010, respectively), whereas MV deceleration time increased significantly (P= 0.006) in response to ivF. Short-axis inferior vena cava diameter (SIVC) in expiration and inspiration and SIVC corrected for body surface area in expiration and inspiration reduced significantly following ivF (P= 0.039, 0.020, 0.032, and 0.016, respectively). BIA estimates of extracellular water decreased significantly (P= 0.001), whereas impedance (Z) at currents of 5, 50, 100, and 200 kHz increased following ivF; the changes were significant with all but the last parameter (P < 0.0001, 0.006, 0.010, and 0.051, respectively). Maximal change from baseline for each parameter was greater than its respective intraobserver variability. Performing repeated measures of echocardiographic and BIA parameters is feasible in this unstable group of patients. The above panel of parameters could potentially be used to track volume response to ivF and, thus, to optimize treatment in acute pulmonary edema.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19426245     DOI: 10.1111/j.1755-5922.2009.00080.x

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN: 1755-5914            Impact factor:   3.023


  5 in total

1.  Monitoring patients with acute dyspnea with serial point-of-care ultrasound of the inferior vena cava (IVC) and the lungs (LUS): a systematic review.

Authors:  Michael Dan Arvig; Christian B Laursen; Niels Jacobsen; Peter Haulund Gæde; Annmarie Touborg Lassen
Journal:  J Ultrasound       Date:  2022-01-18

2.  Dual Impact of Tolvaptan on Intracellular and Extracellular Water in Chronic Kidney Disease Patients with Fluid Retention.

Authors:  Takahiro Masuda; Takuya Murakami; Yusuke Igarashi; Kyochika Okabe; Takahisa Kobayashi; Shin-Ichi Takeda; Takako Saito; Chuji Sekiguchi; Yasuharu Miyazawa; Tetsu Akimoto; Osamu Saito; Shigeaki Muto; Daisuke Nagata
Journal:  Intern Med       Date:  2016-10-01       Impact factor: 1.271

3.  Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease.

Authors:  Izumi Nagayama; Takahiro Masuda; Saki Nakagawa; Takuya Murakami; Ken Ohara; Ryo Matsuoka; Takahisa Kobayashi; Akito Maeshima; Tetsu Akimoto; Osamu Saito; Shigeaki Muto; Daisuke Nagata
Journal:  Intern Med       Date:  2019-02-01       Impact factor: 1.271

4.  Effect of furosemide on body composition and urinary proteins that mediate tubular sodium and sodium transport-A randomized controlled trial.

Authors:  Mose Frank Holden; Anna Ewa Oczachowska-Kulik; Robert Andrew Fenton; Jesper Nørgaard Bech
Journal:  Physiol Rep       Date:  2021-01

5.  Quantification of body fluid compartmentalization by combined time-domain nuclear magnetic resonance and bioimpedance spectroscopy.

Authors:  Jeffrey L Segar; Kirthikaa Balapattabi; John J Reho; Connie C Grobe; Colin M L Burnett; Justin L Grobe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-10-21       Impact factor: 3.619

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.